alexa Use of Transcutaneous Application of CO2 in Diabetic Foot Pathology | Open Access Journals
ISSN: 2329-910X
Clinical Research on Foot & Ankle
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Use of Transcutaneous Application of CO2 in Diabetic Foot Pathology

Igor Frangez1*, Jure Colnaric1, Danijela Truden2

1Department of Traumatology, University Medical Centre Ljubljana, Zaloška Cesta, Ljubljana, Slovenia

2Center for Peripheral Vascular Rehabilitation, Koprska Ulica, Slovenia

*Corresponding Author:
Igor Frangez
Department of Traumatology, University Medical Centre Ljubljana
Zaloška Cesta, Ljubljana, Slovenia
Tel: +386 1 522 3255
Email: [email protected]

Received date: March 27, 2017; Accepted date: April 12, 2017; Published date: April 19, 2017

Citation: Frangez I, Colnaric J, Truden D (2017) Use of Transcutaneous Application of CO2 in Diabetic Foot Pathology. Clin Res Foot Ankle 5:232. doi:10.4172/2329-910X.1000232

Copyright: © 2016 Frangez I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Clinical Research on Foot & Ankle

Abstract

In neuropathic foot ulcers, the most prominent finding is the loss of peripheral sensation and is typically seen in diabetic patients. In addition, vasculopathy may lead to foot ulcerations in diabetic patients. CO2 therapy was found to improve chronic wound healing in patients with vascular impairment. It refers to the transcutaneous and subcutaneous application of CO2 as well as CO2 water baths for therapeutic purpose. In the method used, gaseous CO2 is applied transcutaneously using the PVR system®. CO2 is applied by means of a single-use, low-density polyethylene bag which is wrapped around the leg being treated and secured with an elastic strap. The advantages of this method, compared to injecting CO2 into subcutaneous tissue, are non-invasiveness, the absence of pain and protection against infection. Compared to CO2 balneotherapy this approach enables the use of higher CO2 concentrations, application to chronic wound patients and, with appropriate precautionary measures, prevents the increase of CO2 in the surrounding air. Finzgar et al. observed that the transcutaneous application of gaseous CO2 caused a significant increase in the Laser Doppler (LD) flux in cutaneous microcirculation in vivo in humans. The favourable clinical and microcirculatory effects of gaseous CO2 have further been observed in studies of patients with intermittent claudication as well as patients with primary and secondary Raynaud's phenomenon. The reviewed studies suggest that the increased delivery of CO2 to the ulcerated area will cause vasodilation and an increase in blood flow. The improved angiogenesis and oxygenation will result in healing of the chronic wound. This principle may be applied in the treatment of diabetic foot ulceration. Moreover, the effect on blood flow may also be important in preventive and curative treatment of patients with impaired mobility due to organic or functional causes. Further work is needed for the development of therapeutic strategies to optimize CO2 use in diabetic foot patients.

Keywords

Carbon dioxide therapy; Microcirculation; Contralateral limb; Vasculopathy; Polyneuropathy

Introduction

Carbon dioxide therapy refers to the transcutaneous and subcutaneous application of CO2 as well as CO2 water baths for therapeutic purposes. CO2 rich water bathing has been used since 1930 and was found to improve chronic wound healing in patients with vascular impairment. With neuropathic foot ulcers, the most prominent finding is the loss of peripheral sensation and is typically seen in diabetic patients. Repeated stress and lack of sensation lead to trauma, breakdown of overlying tissue and eventual ulceration. At pressure points, vascular impairment may additionally lead to ulceration.

One major goal of treatment is to improve microcirculation and thereby oxygen supply and the transport of metabolic pathway endproducts. The effects of CO2 therapies on skin microcirculation have been studied in animal models. Duling BR [1] observed increased microvascular diameter and increased perivascular pO2 at sites of exposure to a CO2 aqueous solution. The increased diameter was due to the vasodilatory effect of topical CO2, the phenomenon also known as active hyperaemia. The increased perivascular pO2 was due to the effect of CO2 on the oxyhemoglobin dissociation curve. Irie et al. [2] demonstrated that CO2 immersion induced the production of plasma vascular endothelial growth factor (VEGF), resulting in no-dependent angiogenesis associated with the mobilization of endothelial progenitor cells. Hayashi et al. [3] showed that CO2 immersion increased blood flow in feet to a much higher extent than plain water and it improved the limb salvage rate in critical limb ischemia patients without the option of revascularization. These results showed the potential role of topical CO2 in effective adjunctive treatment to prevent diabetic ulcer exacerbation.

Materials and methods

Gaseous CO2 with 99.995% purity (medical grade) was applied transcutaneously using the PVR system® (produced by DermaArt Ltd., Brezice, Slovenia). The PVR system consists of a compressor, a CO2 level monitoring sensor and a conduit tube for CO2. CO2 was applied by means of a single-use, low-density, polyethylene bag which was wrapped around the leg being treated and tightened with an elastic strap. The 35-minute therapies are performed twice a week over a period of 5 weeks. The PVR system enables the safe and controlled application of a high concentration of CO2 to the body. The method of application is completely safe and prevents any inhalation of CO2. The device also has an electronic sensor system which constantly monitors the air quality in the room.

Discussion

Brandi et al. [4] studied the effect of the subcutaneous application of gaseous CO2 in the treatment of chronic lower limb lesions. Laser Doppler flux and transcutaneous pO2 were measured in two groups. In one group, CO2 therapy was used in addition to the standard methods of treatment for such lesions. The patients in the control group were treated using only standard methods. In the group that underwent subcutaneous treatment with CO2, a significant increase in tissue oxygenation values were observed. They showed progress in healing and a decrease in size of the injured area.

Finzgar et al. [5] conducted a study of the effect of the transcutaneous application of gaseous CO2 on cutaneous blood flow in vivo in humans. The Laser Doppler (LD) flux in cutaneous microcirculation was measured simultaneously in a group of 33 healthy men during rest and a 35-minute CO2 therapy. One lower limb of each subject was exposed to gaseous CO2. The contralateral limb was the control, being exposed to air. The CO2 therapy caused a statistically significant increase in the LD flux of the studied extremity, whereas in the LD flux of the control extremity was not statistically significant. Aside from a minor decrease in heart rate, no systemic effects were found. The LD flux change is most likely an indirect sign of the successful diffusion of CO2 molecules through the skin into microcirculation and a direct indicator of the vasodilatory effect of CO2.

Favorable clinical and microcirculatory effects of gaseous CO2 were further observed in studies of patients with intermittent claudication [6] and patients with primary and secondary Raynaud's phenomenon [7]. The same principle is applied in the treatment of diabetic foot ulceration. The reviewed studies suggest that CO2 therapy can be a safe outpatient treatment option for patients with chronic wounds [8]. There are a number of other possible application for CO2 therapy as well. Indications include intermittent claudication, peripheral artery disease and arteriolar blood flow occlusion/disorders, diabetic feet, diabetic vasculopathy and polyneuropathy, and bedsores. Contraindications include acute pyretic diseases, consumptive diseases and ulcers, severe hypertension, new cardiac infarctions, aortic and mitral valve stenosis, severe congenital heart failure, cor pulmonale, broncho pulmonary diseases accompanied by hypercapnia and acute inflammatory vascular diseases [9].

Conclusion

The reviewed studies suggest that the increased delivery of CO2 to the ulcerated area results in vasodilation and an increase in blood flow. The improved angiogenesis and oxygenation enhances the healing of chronic wounds. This principle may be applied in the treatment of diabetic foot ulcerations. The effect on blood flow may be important in the preventive and curative treatment of patients with impaired mobility due to organic or functional causes. Further work is needed for the development of therapeutic strategies to optimize CO2 use in diabetic foot patients.

Refrences

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 74
  • [From(publication date):
    July-2017 - May 30, 2017]
  • Breakdown by view type
  • HTML page views : 54
  • PDF downloads :20
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version